Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

JPI Conference Dublin Plenary Session Philippe Amouyel


Published on

Presentation delivered by Philippe Amouyel as part of the irish EU Presidency conference on Joint Programming - Feb 28th, 2013

Published in: Health & Medicine
  • Login to see the comments

  • Be the first to like this

JPI Conference Dublin Plenary Session Philippe Amouyel

  1. 1. Joint Programming as a response to societal challengesJoint Programming Initiative on NeurodegenerativeDiseases:The Next Challenges Prof. Philippe Amouyel Chair, JPND Management Board
  2. 2. Alzheimer’s and NeurodegenerativeDiseases in Europe Alzheimer’s Number of cases Societal costs (€) 2010 6,000,000 72,000,000,000 2040 12,000,000 144,000,000,000 A major societal challenge for the coming years
  3. 3. The JPND goals To tackle the challenge of Alzheimer’s and other neurodegenerative diseases*, the goals of the JPND Research Strategy are: • To develop new treatments and preventive strategies • To improve health and social care approaches • To raise awareness and de-stigmatise neurodegenerative disorders • To alleviate the economic and social burden of these diseases* Alzheimer’s disease and other dementias (AD), Parkinson’s disease (PD) and PD-relateddisorders, Prion disease, motor neurone diseases (MND), Huntington’s disease (HD),spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA)
  4. 4. JPND Mapping 2011from
  5. 5. JPND - Clearing Steps• The Foundations • Agree on a Common Vision • Build Trust • Define Terms of Reference • Structure the Governance • Working Together• The Strategic Research Agenda• The Implementation• Towards Sustainability
  6. 6. Governance 27 countries Management Board Executive Scientific Board Advisory Board Jumpahead Steering Committee WP1 WP2 WP3 WP4 WP5
  7. 7. JPND Research Strategy (SRA)• What is it? • A holistic ‘roadmap’ for future EU-wide activity and investment • Not a review of the field, not a list of calls for proposals • Launched Feb 7th, 2012 • 5 research priorities, 9 enabling activities• Delivery has taken into account • SAB recommendations • Outputs from 4 scientific/strategic workshops • National and European portfolios • Mapping exercise of National and European programmes • Broad consultation with stakeholder groups • Both Online and Offline
  8. 8. A European Challenge“The answers to these challenges will be found in science and research.This Research Strategy comes not a moment too soon. It provides amuch-needed framework for European-level coordination and investmentin neurodegenerative disease research.”Mrs Máire Geoghegan-Quinn EuropeanCommissioner for Research, Innovation and ScienceLaunch of the Research Strategy of JPNDBrussels, 7 February 2012
  9. 9. Next Steps• The JPI must have clear and quantifiable scientific objectives to propose • The SRA alone is not sufficient • It is only a holistic roadmap • An implementation plan is compulsory• Objectives must be in-line with the scientific strategy of each country • Some countries have their own National Plan • Others need to build one
  10. 10. The Implementation Plan• Create list of priorities from JPND Research Strategy proposals• Organise thematic working groups• Create list of opportunities suited for implementation• Organise specific task forces• Stimulate and align National Plans• Set action groups for specific priorities and encouraging collaborations• Support implementation
  11. 11. Some achievements• Creation of stable management structure with efficient procedures• Mapping exercise and associated public database• JPND Joint Transnational Calls: • One in 2011 for €15M ; Two in 2012-2013 for €25M• Centres of Excellence in Neurodegeneration program: • 2011 for €6M ; in 2012-13 for €8M• Opening up to Third Countries: • Canada already, on-going discussions with US
  12. 12. The next Challenges• To implement over time• To partner with EU• To partner with industry• To ensure JPND sustainability
  13. 13. To implement over time• Developing attractive programs• Easier when a National Plan already exists• Always « a la carte »• Need for synchronisation of funding decisions in each country (yearly basis)• Strengthing decisions by signing Memorandum of Understanding• Importance of phasing and overlap• Diversity of the tools
  14. 14. To partner with EU• Establish a programme of co-investment• Work towards a sustained increased of the investment amongst JPND partners• Leverage the value of investments and resources at both national and European Commission level, to the benefit of Europe Examples: •Synergy between JPND actions and H2020 programme •Linking national plans through actions engaging national infrastructures •Development and long term sustainability of European cohorts •Unlocking national capability on fellowship program
  15. 15. To partner with Industry• Participation in the Research Strategy delivery• Enlarge the contacts (pharma, device, IT, diagnosis, imaging, welfare technologies, AAL, …)• Ongoing discussions with IMI• Not a single mechanism to interact for companies • access to infrastructures and clinical networks • associate in JPND calls • set up an educational program
  16. 16. To ensure JPND sustainability• JPND is supported by the CA Jumpahead• Improve / achieve efficiency• Provide points of influence of key stakeholders• Inclusive of member states interest• Permanent full time senior management resources• Cash / in-kind contributions from member states• Legal structure
  17. 17. Joining forcesto fight neurodegenerative diseases‘We hope that JPND will be a successful pilot for research intoother challenges, as well as lead to a reduction in the burden ofneurodegenerative diseases.’ Vol 12 February 2013, Editorial p119
  18. 18. Keep up to date• Visit the JPND website: • •• Search our Mapping Database• Sign up to the JPND News Feeds• E-mail us:• Follow us on Twitter: @JPNDEurope